Mechanisms of resistance to EGFR targeted therapies

G Hrustanovic, BJ Lee, TG Bivona - Cancer biology & therapy, 2013 - Taylor & Francis
EGFR is a validated therapeutic target in many human cancers. EGFR targeted therapies
are in widespread clinical use in patients with non-small cell lung cancer and other tumor …

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials

GM O'Kane, TA Barnes, NB Leighl - Current Oncology, 2018 - mdpi.com
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (NSCLCS) that benefit from precision medicine …

PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2+ breast cancer cells by inducing Bim

SH Park, K Ito, W Olcott, I Katsyv… - Breast Cancer …, 2015 - Springer
Introduction Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase that is highly
expressed in Human Epidermal Growth Factor 2+(Her2+) breast cancers. Overexpression of …

[HTML][HTML] BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

AF Cardona, L Rojas, B Wills, O Arrieta, H Carranza… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can have a
crucial role in diverse tumors. To determine the clinical utility of detecting BIM deletion …

Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes

M Rahman, SM MacNeil, DF Jenkins, G Shrestha… - Genome medicine, 2017 - Springer
Background The growth factor receptor network (GFRN) plays a significant role in driving
key oncogenic processes. However, assessment of global GFRN activity is challenging due …

[PDF][PDF] Bringing target-matched PI3King from the bench to the clinic

F Janku - Cell cycle, 2013 - Taylor & Francis
Correspondence to: Filip Janku; Email: fjanku@ mdanderson. org Submitted: 04/26/13;
Accepted: 05/03/13 http://dx. doi. org/10.4161/cc. 25118 Comment on: Janku F, et al …